March 7, 2006 -- Cubicin, an antibiotic from Cubist Pharma, was recommended for an add-on indication by the FDA advisory committee; the FDA sent a “not approvable” letter to Impax Labs concerning Vadova, a generic form of a Parkinson’s disease drug; Baxter Healthcare began a Phase II trial of an adult stem cell therapy as a treatment for coronary artery disease; GenVec completed enrollment in a Phase I study of AdPEDF gene therapy in patients with wet age-related macular degeneration; Bristol-Myers Squibb said the FDA accepted the filing for its leukemia drug and gave it priority review status; Titan Pharma has begun a Phase II trial of DITPA as a cholesterol therapy; Connectics in-licensed a technology that may treat excessive sweating; Compugen will lead a consortium that will simulate the cancer-signalling MAP-kinase pathway; Indevus Pharma filed a new patent application covering use of pagoclone to treat premature ejaculation; and Favrille announced a $45 million private placement of stock. The Centient Biotech 200™ closed 29 points lower at 3958.27, a loss of .77%. More details...
